BioVaxys Technology Corp. (CSE: BIOV) announced this morning that its France-based manufacturing partner, Bio Elpida, has reached milestones in its bioproduction process related to the company’s ovarian cancer vaccine.
The partnership is currently working on the biotech firm’s cancer vaccine candidate BVX-0918A. Bio Elpida has recently concluded technology process transfer with BioVaxys and is expected to now focus on developing the manufacturing process.
“This major step is essentially a ‘dry-run’ for manufacturing the vaccine and preparation for GMP (good manufacturing practice) production,” said Bio Elpida President Gilles Devillers.
As the cancer vaccine producer develops the manufacturing approach, the company relayed that the preparation of the new manufacturing facility is also underway.
Following this milestone, the next step is the vaccine process validation using donated tumor samples obtained from ovarian cancer patients.
The ovarian cancer vaccine candidate is also headed for a planned phase 1 trial in Spain with the biotech firm’s EU commercial partner Procare Health Iberia.
BioVaxys Technology last traded at $0.44 on the CSE.
Information for this briefing was found via Sedar and the companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
